Natera shares are trading higher after the company announced an analysis from the IMvigor011 study in muscle-invasive bladder cancer. Also, Bernstein upgraded the stock from Market Perform to Outperform and announced a $120 price target.
Portfolio Pulse from Benzinga Newsdesk
Natera's stock price increased following the announcement of positive analysis results from the IMvigor011 study in muscle-invasive bladder cancer. Additionally, Bernstein upgraded Natera's stock from Market Perform to Outperform with a $120 price target.
April 05, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's stock is trading higher due to positive study results and an upgrade by Bernstein to Outperform with a $120 price target.
The positive outcome from the IMvigor011 study directly impacts Natera's product credibility and market position in the healthcare sector, likely leading to increased investor confidence. Bernstein's upgrade to Outperform and setting a $120 price target further validates the company's growth prospects, influencing a positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100